35.44
-1.88%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shenyang Xingqi Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 300573.SZ. It has been listed since 8 December 2016. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.47bn and net income of CN¥695.9m. At that date it held total assets of CN¥2.54bn and shareholders' equity of CN¥1.98bn.
Shenyang Xingqi Pharmaceutical Co., Ltd. principally engages in the research, development, production, and sale of ophthalmic drugs. The company is headquartered in Shenyang, Liaoning. The company went IPO on 2016-12-08. The Company’s main products are ophthalmic prescription drugs, including corneal repairing drugs, anti-bacteria drugs, artificial tears, anti-inflammation drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. The firm mainly distributes its products within domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 8 Dec 2016
- Employees
- 1,763
- Website
- sinqi.com ↗
Leadership
Pay as last reported
- Mr. Jidong LiuChairman of the Board, since 2011CN¥6.0m
- Mr. Shaoyao ZhangVice Chairman of the Board, Deputy General Manager, Secretary of the Board, since 2011CN¥2.3m
- Ms. Yanan ChengChief Financial Officer, Deputy General Manager, Director, since 2011CN¥1.9m
- Mr. Chunhua LiChief Administrative Officer, Director, since 2022CN¥1.4m
- Ms. E GaoGeneral Manager, Director, since 2011CN¥2.3m
- Mr. Qiang YangDeputy General Manager, Director, Head of R&D Center, since 2017CN¥1.6m
- Mr. Xiaobin DaiIndependent DirectorCN¥147,400
- Ms. Xiaoyan KongIndependent DirectorCN¥147,400
- Ms. Xianmei XuIndependent DirectorCN¥147,400
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shenyang Xingqi Pharmaceutical employs 1,763 full-time employees for ophthalmic drug production.
- The company's main products include corneal repairing and anti-bacteria drugs in the domestic market.
- Shenyang Xingqi Pharmaceutical has an IPO listing date of 8 December 2016.
Weaknesses
- Shenyang Xingqi Pharmaceutical operates solely within the domestic market of China.
- The company's business is limited to ophthalmic prescription drugs without diversification.
- Shenyang Xingqi Pharmaceutical has no international presence or global market expansion.
Opportunities
- Shenyang Xingqi Pharmaceutical can expand into ophthalmic drug markets in other Asian countries.
- The company could develop new artificial tears and anti-inflammation drugs for domestic demand.
- Shenyang Xingqi Pharmaceutical may leverage its 1,763 employees for product innovation.
Threats
- Shenyang Xingqi Pharmaceutical faces competition from domestic pharmaceutical companies in China.
- The company's reliance on the domestic market exposes it to economic fluctuations in China.
- Shenyang Xingqi Pharmaceutical has no international market to offset domestic challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.